

Hutchison Whampoa Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 013)

OVERSEAS REGULATORY ANNOUNCEMENT

Please refer to the attached announcement of Hutchison China MediTech Limited, which is listed on the Alternative Investment Market operated by the London Stock Exchange and a 71.6% owned subsidiary of Hutchison Whampoa Limited.

As at the date of the announcement, the Directors of Hutchison Whampoa Limited are:

Executive Directors:

Mr. LI Ka-shing (*Chairman*)
Mr. LI Tzar Kuoi, Victor (*Deputy Chairman*)
Mr. FOK Kin-ning, Canning
Mrs. CHOW WOO Mo Fong, Susan
Mr. Frank John SIXT
Mr. LAI Kai Ming, Dominic
Mr. KAM Hing Lam

Non-executive Directors:

Mr. George Colin MAGNUS
Mr. William SHURNIAK

Independent Non-executive Directors:

The Hon. Sir Michael David KADOORIE
Mr. Holger KLUGE
Mr. William Elkin MOCATTA
(Alternate to The Hon. Sir Michael David Kadoorie)
Mr. OR Ching Fai, Raymond
Mr. WONG Chung Hin

Hong Kong, 27 December 2007



HUTCHISON CHINA MEDITECH LTD

**Hutchison China MediTech Limited (“Chi-Med”)
(AIM: HCM)**

Block Admission Return

London, Thursday, 27 December 2007: Chi-Med announces the following block admission return:

Name of the company:	Hutchison China MediTech Limited
Name of the scheme:	Hutchison China MediTech Limited Share Option Scheme
Period of return:	From 26 June 2007 to 26 December 2007
Number and class of securities not issued under the scheme at the beginning of the period:	2,560,606 ordinary shares of US\$1 each
Number of securities issued under the scheme during the period:	17,053 ordinary shares of US\$1 each
Balance under the scheme of securities not yet issued at the end of the period:	2,543,553 ordinary shares of US\$1 each
Number and class of securities originally admitted and the date of admission:	2,560,606 ordinary shares of US\$1 each admitted on 26 June 2007

The total number of securities in issue at the end of the period was 51,229,174 ordinary shares of US\$1 each.

- Ends -

Enquiries

Chi-Med

Telephone: +852 2121 8200

Christian Hogg, CEO

Citigate Dewe Rogerson

Telephone: +44 (0) 20 7638 9571

Anthony Carlisle
Yvonne Alexander

Mobile: +44 (0) 7973 611 888
Mobile: +44 (0) 7866 610 682

About Chi-Med

Chi-Med is the holding company of a pharmaceutical and healthcare group based primarily in China and was admitted to trading on the Alternative Investment Market of the London Stock Exchange in May 2006. Chi-Med focuses on research, development, manufacture and sale of pharmaceuticals, health supplements and other consumer health and personal care products derived from Traditional Chinese Medicine and botanical ingredients.

Chi-Med is majority owned by Hutchison Whampoa Limited, an international corporation listed on the Main Board of The Stock Exchange of Hong Kong Limited.